FdaApplication
NDA 214103
Identifiers
- fda_app_no: NDA214103
Properties
| Property | Value |
|---|---|
| applicant_name | ALNYLAM PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2020-11-23 |
Revenue by product
OXLUMO
| Period | Revenue |
|---|---|
| Q2 2026 | $52.1M |
| Q1 2026 | $51.3M |
| Q3 2025 | $52.8M |
| Q2 2025 | $46.9M |
| Q1 2025 | $42.1M |
| Q4 2024 | $43.6M |
| Q3 2024 | $40.2M |
| Q2 2024 | $40.6M |
| Q1 2024 | $42.6M |
| Q4 2023 | $32.7M |
| Q3 2023 | $28.7M |
| Q2 2023 | $24.2M |
| Q1 2023 | $24.2M |
| Q4 2022 | $23.8M |
| Q3 2022 | $16.4M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| OXLUMO | LUMASIRAN SODIUM | EQ 94.5MG BASE/0.5ML (EQ 94.5MG BASE/0.5ML) | SOLUTION;SUBCUTANEOUS |
1 product